EFTX-G12V / EnFuego Therapeutics - LARVOL DELTA

Preclinical development of EFTX-G12V, a first-in-class EGFR-directed KRAS G12V selective inhibitor (AACR 2026) - "Lastly, we recently completed non-GLP safety studies in rat and mini-pig models and observed no test article related clinical observations, no injection site reactions and initial gross pathology detected no visible lesions across all tissues. Together these data indicate that EFTX-G12V has therapeutic efficacy in multiple cancer models, is delivered to tumor tissue with minimal somatic tissue exposure, and may be well tolerated."

Preclinical • Oncology • Pancreatic Cancer • Skin Cancer • Solid Tumor • EGFR • KRAS